Polycystic ovary syndrome (PCOS) was officially renamed to polyendocrine metabolic ovarian syndrome (PMOS) in May 2026. The diagnostic criteria remain the same (2 of 3 Rotterdam criteria), but the clinical emphasis shifts toward metabolic and endocrine management. First-line fertility treatment is letrozole, with inositol, metformin, and lifestyle intervention as key adjuncts.
Key Takeaways
PCOS was renamed PMOS in May 2026 via a Lancet consensus paper — same condition, more accurate name reflecting metabolic and endocrine dimensions
Diagnosis still requires 2 of 3 Rotterdam criteria: irregular periods, hyperandrogenism, and/or polycystic ovarian morphology
Letrozole has replaced clomid as the first-line ovulation induction medication, with a 27.5% vs 19.1% live birth rate advantage
The metabolic framing means providers should now screen insulin, glucose, and lipids at diagnosis — not just when fertility treatment begins
PCOS Is Now PMOS: What Changed and Why
On May 12, 2026, a landmark consensus paper published in The Lancet officially renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS). The change followed over a decade of international collaboration involving 56 patient and professional organizations and more than 22,000 survey responses from clinicians, researchers, and patients worldwide.
The rename wasn't cosmetic. The old name — "polycystic ovary syndrome" — was clinically misleading. The "cysts" visible on ultrasound are actually small antral follicles (immature follicles that haven't developed properly), not pathological cysts. And the condition extends far beyond the ovaries into metabolic, endocrine, cardiovascular, and mental health territory.
The new name captures three critical dimensions that the old one obscured:
- Polyendocrine: Reflects the multi-hormone dysfunction (insulin, androgens, LH, AMH) that drives the condition
- Metabolic: Acknowledges the insulin resistance, cardiometabolic risk, and systemic inflammation at the core of PMOS
- Ovarian: Retains the ovary's role — follicle development and ovulation are key features — without reducing the entire condition to ovarian "cysts"
According to the Lancet consensus, 86% of patients and 71% of clinicians supported the name change. Primary motivations: reducing stigma, improving diagnostic accuracy, and shifting care from symptom management to addressing upstream metabolic drivers.
How PMOS Is Diagnosed in 2026
The diagnostic criteria haven't changed with the rename — you still need 2 of 3 Rotterdam criteria (after excluding other causes):
| Criterion | What It Means | How It's Assessed |
|---|---|---|
| Oligo/anovulation | Irregular or absent periods (cycles >35 days or <8 cycles/year) | Menstrual history tracking |
| Hyperandrogenism | Elevated male hormones — clinical (acne, hirsutism, hair loss) or biochemical (elevated testosterone/DHEA-S) | Blood work + physical exam |
| Polycystic ovarian morphology | ≥12 antral follicles per ovary or ovarian volume >10 mL on ultrasound | Transvaginal ultrasound |
What is changing is the clinical emphasis. With PMOS framing, providers are increasingly screening for metabolic markers at diagnosis — not just when symptoms escalate. This means earlier intervention on insulin resistance, lipid panels, and cardiovascular risk factors.
💡 If you were previously diagnosed with PCOS, your diagnosis is still valid. PMOS is the same condition with a more accurate name. You don't need to be re-evaluated unless your treatment plan isn't working.
The Four PMOS Phenotypes
Not all PMOS presents the same way. Understanding your phenotype helps tailor treatment:
| Phenotype | Features | Fertility Impact | Metabolic Risk |
|---|---|---|---|
| A (Classic) | Irregular periods + high androgens + polycystic ovaries | High — anovulation common | Highest |
| B (Classic) | Irregular periods + high androgens (no polycystic morphology) | High | High |
| C (Ovulatory) | Regular cycles + high androgens + polycystic ovaries | Moderate — may still ovulate | Moderate |
| D (Non-hyperandrogenic) | Irregular periods + polycystic ovaries (normal androgens) | Moderate-High | Lower |
First-Line Treatments for PMOS-Related Infertility
Lifestyle Intervention
For patients with elevated BMI, even a 5–10% reduction in body weight can restore ovulation in up to 60% of cases. But PMOS also affects lean individuals — roughly 20–30% of patients have a normal BMI. Lifestyle intervention for lean PMOS focuses on anti-inflammatory nutrition, stress management, and targeted supplementation rather than caloric restriction.
Letrozole (Femara)
Letrozole has replaced clomiphene citrate as the first-line ovulation induction agent for PMOS. The landmark NICHD trial demonstrated significantly higher live birth rates with letrozole (27.5%) compared to clomid (19.1%), with lower rates of multiple pregnancy.
Metformin
Metformin addresses the insulin resistance driving many PMOS symptoms. While not as effective as letrozole for ovulation induction alone, it's often combined with letrozole for patients with significant insulin resistance. The combination may improve outcomes in clomid/letrozole-resistant patients.
Inositol Supplementation
Myo-inositol and D-chiro-inositol (in a 40:1 ratio) have emerged as evidence-backed adjuncts for PMOS. Multiple meta-analyses show improvements in insulin sensitivity, androgen levels, and ovulation rates. While not a replacement for medical treatment, inositol is increasingly recommended alongside conventional therapy.
For detailed supplement protocols, see our sister site's guide: Myo-Inositol vs D-Chiro: Complete PMOS Guide.
Gonadotropins
When oral medications fail, injectable gonadotropins (FSH) with careful monitoring can stimulate follicle development. The "low-dose step-up" protocol is preferred for PMOS to minimize the risk of ovarian hyperstimulation syndrome (OHSS) and multiple pregnancies.
Ovarian Drilling
Laparoscopic ovarian drilling (LOD) is a surgical option for letrozole/clomid-resistant PMOS. Small holes are made in the ovarian surface using laser or diathermy, temporarily reducing androgen production and often restoring ovulation for 6–12 months. It's fallen out of favor as IVF outcomes have improved.
When IVF Becomes the Next Step
IVF is typically recommended for PMOS patients after 3–6 failed cycles of ovulation induction, or when other factors (tubal disease, male factor, age) are present. PMOS patients often respond robustly to IVF stimulation — sometimes too robustly.
⚠️ PMOS patients are at higher risk for OHSS during IVF. Modern protocols mitigate this with GnRH antagonist protocols, trigger with agonist instead of hCG, and freeze-all strategies. Make sure your RE has specific PMOS/IVF experience.
The good news: PMOS patients who reach egg retrieval typically have excellent egg yields. The challenge is quality over quantity — not every egg will be mature or chromosomally normal. But cumulative pregnancy rates across multiple frozen embryo transfers are quite favorable.
The Metabolic Side: Why It Matters for Pregnancy
PMOS-related metabolic dysfunction doesn't stop at conception. Patients with PMOS face elevated risks during pregnancy:
- Gestational diabetes: 2–4x higher risk than the general population
- Pre-eclampsia: 2–3x elevated risk
- Preterm birth: Modestly increased risk
- Macrosomia: Larger birth weight babies, especially with gestational diabetes
This is exactly why the rename matters clinically — framing PMOS as a metabolic condition means providers are more likely to screen for and manage these risks proactively throughout pregnancy, not just during fertility treatment.
What the Name Change Means for You Right Now
If you're currently in treatment or searching for answers, here's what's practical:
- Your diagnosis is unchanged. PMOS = PCOS with a better name. No re-testing needed.
- Insurance codes are transitioning. The rollout is planned over 3 years across 195 countries. Most insurance still uses PCOS codes (E28.2) — expect a gradual ICD update.
- Ask your doctor about metabolic screening. The rename should prompt more comprehensive baseline testing: fasting insulin, glucose tolerance, lipid panel, and HbA1c — even if you're lean.
- Search for both terms. Research, support groups, and educational content will use both PCOS and PMOS during the transition period. Neither is "wrong."
For supplement approaches to PMOS management, visit NAC for Fertility and PMOS on LifeFertile. For the emotional journey of a PMOS diagnosis, FertileStart has validation-first resources.